著者

池田 康将 土屋 浩一郎 玉置 俊晃

出版者

一般社団法人 日本糖尿病学会

雑誌

糖尿病 (ISSN:0021437X)

巻号頁・発行日

vol.56, no.12, pp.919-921, 2013-12-30 (Released:2014-01-15)

参考文献数

5

被引用文献数

1

著者

清水 寛 土屋 浩一郎 桜井 弘

出版者

和漢医薬学会大会

雑誌

和漢医薬学会大会要旨集

巻号頁・発行日

vol.7, 1990

著者

宮本 理人 土屋 浩一郎

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.138, no.7, pp.933-938, 2018-07-01 (Released:2018-07-01)

参考文献数

11

被引用文献数

3 3

---

Sodium-glucose transporter (SGLT)-2 inhibitors, which are currently in clinical use in most of the world, are unique as their hypoglycemic effects are completely independent of insulin action. Potential benefits and indications for the treatment of other diseases like circulatory and renal disorders are attracting attention. SGLT2 inhibitors not only reduce blood glucose levels but also alter the whole-body energy balance to lower body weight, which should result in the amelioration of multiple metabolic disorders like metabolic syndrome. In the symposium, we briefly introduced the physiological as well as biological functions of SGLTs and discussed strategies for drug design by looking back at the history of drug discovery for SGLT2 inhibitors. We also shared our recent data on their combined usage with other hypoglycemic agents and effects on glucagon secretion, which are current clinical topics relevant to SGLT2 inhibitors. Among those topics, strategies for drug discovery of SGLT2 inhibitors are discussed in this review.

著者

土屋浩一郎編著

出版者

京都廣川書店

巻号頁・発行日

2013